Betriu C, Sánchez A, Gómez M, Palau M L, Picazo J J
Servicio de Microbiología Clínica, Hospital Clínico San Carlos, Madrid, Spain.
J Antimicrob Chemother. 1999 Jan;43(1):133-6. doi: 10.1093/jac/43.1.133.
The in-vitro activities of imipenem and four beta-lactam-beta-lactamase inhibitor combinations were tested against 816 strains of the Bacteroides fragilis group, and compared with other anti-anaerobic agents. None of the strains was resistant to metronidazole, and only one was resistant to chloramphenicol. Mezlocillin and piperacillin were moderately active, while clindamycin was the least active. Rates of resistance varied between various species. The new beta-lactam agents tested showed excellent activity; piperacillin-tazobactam and imipenem were the most active. The emergence of strains that are resistant to these agents, observed in this study, suggests there is a need to perform periodic antimicrobial susceptibility tests.
对816株脆弱拟杆菌属菌株测试了亚胺培南及四种β-内酰胺-β-内酰胺酶抑制剂组合的体外活性,并与其他抗厌氧菌药物进行了比较。所有菌株对甲硝唑均不耐药,仅1株对氯霉素耐药。美洛西林和哌拉西林活性中等,而克林霉素活性最低。不同菌种之间的耐药率有所不同。所测试的新型β-内酰胺类药物显示出优异的活性;哌拉西林-他唑巴坦和亚胺培南活性最强。本研究中观察到对这些药物耐药的菌株的出现,提示有必要定期进行抗菌药物敏感性试验。